Similar articles

• Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience.

  Ichikura H, Tanabe K, Tokumoto T, Shimuzu T, Ishikawa N, Harano M, Inui M, Manu M, Ito S, Shimmura H, Okuda H, Yagisawa T, Fuchinoue S, Toma H. Ichikura H, et al. Transplant Proc. 2000 Nov;32(7):1733-5. doi: 10.1016/s0041-1345(00)01396-8. Transplant Proc. 2000. PMID: 11119911 No abstract available.
• Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation.

  Kliem V, Radermacher J, Hiss M, Pethig M, Burg M, Brunkhorst R. Kliem V, et al. Transplant Proc. 1999 Nov;31(7A):37S-40S. doi: 10.1016/s0041-1345(99)00792-7. Transplant Proc. 1999. PMID: 10576041 No abstract available.
• Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach.

  Turner CD, Bruce DS, Cronin DC, Loss GE, Grewal H, Siegel C, Millis JM, Newell KA, Davis B, Todo T, Thistlethwaite JR, Woodle ES. Turner CD, et al. Transplant Proc. 1998 Jun;30(4):1234-5. doi: 10.1016/s0041-1345(98)00223-1. Transplant Proc. 1998. PMID: 9636501 Clinical Trial. No abstract available.
• Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?

  Nashan B. Nashan B. Transplant Rev (Orlando). 2009 Jan;23(1):47-52. doi: 10.1016/j.trre.2008.08.005. Transplant Rev (Orlando). 2009. PMID: 19027616 Review.
• Vascular rejection with tacrolimus and potential long-term graft outcome.

  Vanrenterghem Y. Vanrenterghem Y. Transplant Proc. 1999 Nov;31(7A):86S-87S. doi: 10.1016/s0041-1345(99)00805-2. Transplant Proc. 1999. PMID: 10576054 Review. No abstract available.